Found: 13
Select item for more details and to access through your institution.
Reply.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
Reply.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
Ustekinumab for the Treatment of Giant Cell Arteritis.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
- Published in:
- Arthritis Care & Research, 2017, v. 69, n. 7, p. 1004, doi. 10.1002/acr.23099
- By:
- Publication type:
- Article
Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
- Published in:
- 2016
- By:
- Publication type:
- journal article
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.
- Published in:
- Rheumatology, 2022, v. 61, n. 7, p. 2915, doi. 10.1093/rheumatology/keab780
- By:
- Publication type:
- Article
272 Acute phase reactant levels and prednisone doses at disease flare in patients with giant cell arteritis: prospective data from the GiACTA trial.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
O26 Effects of baseline prednisone dose on remission and disease flare in patients with giant cell arteritis treated with tocilizumab in the GiACTA trial.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
Design of the Tocilizumab in Giant Cell Arteritis Trial.
- Published in:
- International Journal of Rheumatology, 2013, p. 1, doi. 10.1155/2013/912562
- By:
- Publication type:
- Article
Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.
- Published in:
- Arthritis & Rheumatology, 2019, v. 71, n. 8, p. 1329, doi. 10.1002/art.40876
- By:
- Publication type:
- Article
A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis.
- Published in:
- Arthritis Research & Therapy, 2023, v. 25, n. 1, p. 1, doi. 10.1186/s13075-023-03177-6
- By:
- Publication type:
- Article
The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial.
- Published in:
- Rheumatology & Therapy, 2022, v. 9, n. 2, p. 497, doi. 10.1007/s40744-021-00411-y
- By:
- Publication type:
- Article
A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis.
- Published in:
- Rheumatology & Therapy, 2020, v. 7, n. 4, p. 793, doi. 10.1007/s40744-020-00227-2
- By:
- Publication type:
- Article